New five-year data confirms Bictegravir/Emtricitabine/Tenofovir Alafenamide effectively treats advanced HIV cases with high viral loads and low CD4 counts.
Real-world evidence confirms DTG+3TC as an effective, tolerable HIV treatment with high virologic suppression rates and low resistance development.
Explore how potent antiretroviral drugs and sensitive assays transformed HIV treatment and monitoring in 2010, while significant challenges remained.
Explore how fostemsavir provides durable viral suppression and immune recovery for heavily treatment-experienced people with HIV through the BRIGHTE trial data.
Exploring the five-year success of ibalizumab for multidrug-resistant HIV patients, with data visualizations and clinical trial insights.
Discover how Rapid Start Antiretroviral Therapy (RSA) is transforming HIV care by initiating treatment on the same day as diagnosis, dramatically accelerating viral suppression rates.
Analysis of the XV International HIV Drug Resistance Workshop findings on HIV drug resistance patterns, transmission trends, and emerging treatments.